News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Kristijan H. Kahler, SM

Articles by Kristijan H. Kahler, SM

Tegaserod Treatment for IBS: A Model of Indirect Costs

ByDean G. Smith, PhD,Victoria Barghout, MSPH,Kristijan H. Kahler, SM

April 15th 2005

Effectiveness of Tegaserod Therapy on GI-related Resource Utilization in a Managed Care Population

ByJudith J. Stephenson, SM,Victoria Barghout, MSPH,Kristijan H. Kahler, SM,Joaquim Fernandes, BA,Jane F. Beaulieu, MSN,Samuel Joo, MS,Stephen J. Boccuzzi, PhD

April 15th 2005

Budget Impact of Tegaserod on a Managed Care Organization Formulary

ByMichael A. Bloom, BA,Victoria Barghout, MSPH,Kristijan H. Kahler, SM,Judith Bentkover, PhD,Hannah Kurth, BA,Ian M. Gralnek, MD, MSHS,Brennan M. R. Spiegel, MD, MSHS

April 15th 2005

Impairment in Work Productivity and Health-related Quality of Life in Patients With IBS

ByBonnie B. Dean, PhD,Daniel Aguilar, MPH,Victoria Barghout, MSPH,Kristijan H. Kahler, SM,Feride Frech, MPH,David Groves, PhD,Joshua J. Ofman, MD

April 15th 2005

Latest Updated Articles

Tegaserod Treatment for IBS: A Model of Indirect Costs
April 15th 2005
Effectiveness of Tegaserod Therapy on GI-related Resource Utilization in a Managed Care Population
April 15th 2005
Budget Impact of Tegaserod on a Managed Care Organization Formulary
April 15th 2005
Impairment in Work Productivity and Health-related Quality of Life in Patients With IBS
April 15th 2005

Trending on AJMC

FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke

How Plans, Clinicians Should Handle Gray-Market Retatrutide

IVF Beats IUI for Early Live Births in Unexplained Infertility

Phase 3 Data Back ALP Normalization as Treatment Goal in PBC

Combination Therapy Expected in Narcolepsy: David T. Plante, MD, PhD